Artelo Biosciences Inc (ARTL) |
|
1.52 -0.04 (-2.56%)
|
03-07 04:02 |
|
Open: |
1.55 |
Pre. Close: |
1.56 |
|
High:
|
1.59 |
Low:
|
1.29 |
|
Volume:
|
1,826,204 |
Market Cap:
|
24M |
|
|
|
|
Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company is headquartered in La Jolla, California and currently employs 1 full-time employees. The firm is focused on licensing, developing and commercializing treatments intended to modulate the endocannabinoid system (ECS). The company develops and commercializes ethical pharmaceutical products that provide physicians access to the therapeutic potential of cannabinoid therapeutics and other modulators of the ECS for their patients. Its pipeline includes ART12.11, ART26.12 and ART27.13. The firm is developing ART12.11 for targeting the development in Inflammatory Bowel Disease (IBD), stroke and rare/orphan diseases. ART26.12 is its endocannabinoid transport protein (FABP5) inhibitor for treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain. ART27.13 is being developed for cancer. The firm also intends to develop a formulation suitable for treatment of anorexia/weight loss associated with cancer (cachexia). |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.592 - 1.604 |
1.604 - 1.612 |
|
Low:
|
1.266 - 1.278 |
1.278 - 1.288 |
|
Close:
|
1.5 - 1.52 |
1.52 - 1.535 |
|
Technical analysis |
as of: 2021-03-05 5:05:06 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 3.05  One year: 4.29 |
| Support: |
Support1: 0.90 Support2: 0.75 |
| Resistance: |
Resistance1: 2.61 Resistance2: 3.67 |
| Pivot: |
2.16  |
| Moving Average: |
MA(5): 1.80 MA(20): 1.99
MA(100): 0.98 MA(250): 1.05 |
| MACD: |
MACD(12,26): 0.11 Signal(9): 0.23 |
| Stochastic oscillator: |
%K(14,3): 9.44 %D(3): 17.27 |
| RSI: |
RSI(14): 45.00 |
| 52-week: |
High: 3.67 Low: 0.45 Change(%): 52.0 |
| Average Vol(K): |
3-Month: 951580 10-Days: 257813 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.ARTL has closed above bottom band by 10.1%. Bollinger Bands are 177.5% wider than normal. The large width of the bands suggest high volatility as compared to ARTL's normal range. The bands have been in this wide range for 21 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 05 Mar 2021
Artelo Biosciences Inc (ARTL) Up 5.77% in Premarket Trading - InvestorsObserver
Tue, 02 Mar 2021
Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th - GlobeNewswire
Mon, 01 Mar 2021
Is Artelo Biosciences Inc (ARTL) Stock a Smart Investment Monday? - InvestorsObserver
Wed, 17 Feb 2021
Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal - Yahoo Finance
Tue, 16 Feb 2021
BioMedNewsBreaks – Artelo Biosciences Inc. (NASDAQ: ARTL) Appoints Senior Pharmaceutical Exec as New SVP, Chief Scientific Officer - StreetInsider.com
Tue, 16 Feb 2021
Artelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
16 |
| Shares Float (M) |
13 |
|
% Held by Insiders
|
7.82 |
|
% Held by Institutions
|
28.85 |
|
Shares Short (K)
|
1,060 |
|
Shares Short P. Month (K)
|
593 |
Stock Financials |
|
EPS
|
-0.882 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
0.600 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-39.6 |
|
Return on Equity (ttm)
|
-68.3 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.304 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-5 |
|
Levered Free Cash Flow (M)
|
-3 |
Stock Valuations |
|
PE Ratio
|
-1.72 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.53 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-5.18 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2019-06-19 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
